Excess 25-hydroxyVitamin D3 exacerbates tubulointerstitial injury in mice by modulating macrophage phenotype

Kidney International

Volumn 88, Issue 5, 2015, Pages 1013-1029

  Kusunoki, Yasuo ^a   Matsui, Isao ^a   Hamano, Takayuki ^a   Shimomura, Akihiro ^a   Mori, Daisuke ^a   Yonemoto, Sayoko ^a   Takabatake, Yoshitsugu ^a   Tsubakihara, Yoshiharu ^a   St Arnaud, René ^b,c   Isaka, Yoshitaka ^a   Rakugi, Hiromi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Fibrosis; Macrophages; Oxidative stress

Indexed keywords

25 HYDROXYVITAMIN D; 25 HYDROXYVITAMIN D 1ALPHA HYDROXYLASE; ALPHA SMOOTH MUSCLE ACTIN; CALCIFEDIOL; CALCIUM; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRONECTIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MANNOSE RECEPTOR; MANNOSE RECEPTOR C TYPE 1; MESSENGER RNA; OXYGENASE; PARATHYROID HORMONE; PHOSPHATE; SECALCIFEROL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL RECEPTOR; TGFB1 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; KIDNEY TUBULE DAMAGE; KNOCKOUT MOUSE; MACROPHAGE; MACROPHAGE CULTURE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; TUBULOINTERSTITIAL INJURY; UPREGULATION; UREA NITROGEN BLOOD LEVEL; ANIMAL; C57BL MOUSE; CELL CULTURE; COMPLICATION; DRUG EFFECTS; FIBROSIS; GENETICS; KIDNEY TUBULE; METABOLISM; PATHOLOGY; URETER OBSTRUCTION;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; CALCIFEDIOL; CELLS, CULTURED; FEMALE; FIBROSIS; KIDNEY TUBULES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PHENOTYPE; RECEPTORS, CALCITRIOL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; URETERAL OBSTRUCTION;

EID: 84947557252     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.210     Document Type: Article

References (56)

1. DeLuca HF. Overview of general physiologic features and functions of Vitamin D. Am J Clin Nutr 2004; 80: 1689S-1696S.
2. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of Vitamin D. Physiol Rev 1998; 78: 1193-1231.
3. Ferre S, Hoenderop JG, Bindels RJ. Sensing mechanisms involved in Ca2+ and Mg2+ homeostasis. Kidney Int 2012; 82: 1157-1166.
4. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008; 8: 685-698.
5. Gurlek A, Pittelkow MR, Kumar R. Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyVitamin D(3): implications in cell growth and differentiation. Endocr Rev 2002; 23: 763-786.
6. Martinez I, Saracho R, Montenegro J et al. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11: 22-28.
7. Nakano C, Hamano T, Fujii N et al. Combined use of Vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 2012; 7: 810-819.
8. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382-3393.
9. Matsui I, Hamano T, Tomida K et al. Active Vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant 2009; 24: 2354-2361.
10. Inoue K, Matsui I, Hamano T et al. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3. Lab Invest 2012; 92: 1686-1697.
11. de Zeeuw D, Agarwal R, Amdahl M et al. Selective Vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551.
12. Ravani P, Malberti F, Tripepi G et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75: 88-95.
13. Melamed ML, Astor B, Michos ED et al. 25-HydroxyVitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol 2009; 20: 2631-2639.
14. deBoer IH, Ioannou GN, Kestenbaum B et al. 25-HydroxyVitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50: 69-77.
15. Hamano T, Nakano C, Obi Y et al. Fibroblast growth factor 23 and 25-hydroxyVitamin D levels are associated with estimated glomerular filtration rate decline. Kidney Int Suppl (2011) 2013; 3: 469-475.
16. Dusso AS. Kidney disease and Vitamin D levels: 25-hydroxyVitamin D, 1,25-dihydroxyVitamin D, and VDR activation. Kidney Int Suppl (2011) 2011; 1: 136-141.
17. Morris HA. Vitamin D activities for health outcomes. Ann Lab Med 2014; 34: 181-186.
18. Michaëlsson K, Baron JA, Snellman G et al. Plasma Vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr 2010; 92: 841-848.
19. Sempos CT, Durazo-Arvizu RA, Dawson-Hughes B et al. Is there a reverse J-shaped association between 25-hydroxyVitamin D and all-cause mortality? Results from the U. S. nationally representative NHANES. J Clin Endocrinol Metab 2013; 98: 3001-3009.
20. Melamed ML, Michos ED, Post W et al. 25-HydroxyVitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637.
21. Bischoff-Ferrari HA, Willett WC, Orav EJ et al. A pooled analysis of Vitamin D dose requirements for fracture prevention. N Engl J Med 2012; 367: 40-49.
22. Glendenning P, Zhu K, Inderjeeth C et al. Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. J Bone Miner Res 2012; 27: 170-176.
23. Smith H, Anderson F, Raphael H et al. Effect of annual intramuscular Vitamin D on fracture risk in elderly men and women-a populationbased, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) 2007; 46: 1852-1857.
24. Sanders KM, Stuart AL, Williamson EJ et al. Annual high-dose oral Vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303: 1815-1822.
25. Shephard RM, Deluca HF. Plasma concentrations of Vitamin D3 and its metabolites in the rat as influenced by Vitamin D3 or 25-hydroxyVitamin D3 intakes. Arch Biochem Biophys 1980; 202: 43-53.
26. Hughes MR, Baylink DJ, Gonnerman WA et al. Influence of dietary Vitamin D3 on the circulating concentration of its active metabolites in the chick and rat. Endocrinology 1977; 100: 799-806.
27. Rizzoli R, Stoermann C, Ammann P et al. Hypercalcemia and hyperosteolysis in Vitamin D intoxication: effects of clodronate therapy. Bone 1994; 15: 193-198.
28. Vieth R. Vitamin D toxicity, policy, and science. J Bone Miner Res 2007; 22: V64-V68.
29. Dardenne O, Prud'homme J, Arabian A et al. Targeted inactivation of the 25-hydroxyVitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudoVitamin D-deficiency rickets. Endocrinology 2001; 142: 3135-3141.
30. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009; 75: 1145-1152.
31. Jones G. Pharmacokinetics of Vitamin D toxicity. Am J Clin Nutr 2008; 88: 582S-586S.
32. DeLuca HF. Vitamin D and the parenteral nutrition patient. Gastroenterology 2009; 137: S79-S91.
33. Kream BE, Jose MJ, DeLuca HF. The chick intestinal cytosol binding protein for 1,25-dihydroxyVitamin D3: a study of analog binding. Arch Biochem Biophys 1977; 179: 462-468.
34. Wecksler WR, Okamura WH, Norman AW. Studies on the mode of action of Vitamin D-XIV. Quantitative assessment of the structural requirements for the interaction of 1 alpha, 25-dihydroxyVitamin D3 with its chick intestinal mucosa receptor system. J Steroid Biochem 1978; 9: 929-937.
35. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest 2008; 118: 3522-3530.
36. Wang H, Peters T, Sindrilaru A et al. Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis. J Invest Dermatol 2009; 129: 1100-1114.
37. Lee S, Huen S, Nishio H et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 2011; 22: 317-326.
38. Kitamoto K, Machida Y, Uchida J et al. Effects of liposome clodronate on renal leukocyte populations and renal fibrosis in murine obstructive nephropathy. J Pharmacol Sci 2009; 111: 285-292.
39. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28.
40. Wu MY, Hill CS. Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell 2009; 16: 329-343.
41. Miyoshi H, Ajima R, Luo CT et al. Wnt5a potentiates TGF-beta signaling to promote colonic crypt regeneration after tissue injury. Science 2012; 338: 108-113.
42. Massague J, Xi Q. TGF-beta control of stem cell differentiation genes. FEBS Lett 2012; 586: 1953-1958.
43. Bottinger EP. TGF-beta in renal injury and disease. Semin Nephrol 2007; 27: 309-320.
44. Eddy AA. Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl (2011) 2014; 4: 2-8.
45. Rowling MJ, Gliniak C, Welsh J et al. High dietary Vitamin D prevents hypocalcemia and osteomalacia in CYP27B1 knockout mice. J Nutr 2007; 137: 2608-2615.
46. Sindrilaru A, Peters T, Wieschalka S et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest 2011; 121: 985-997.
47. Chen Y, Liu W, Sun T et al. 1,25-DihydroxyVitamin D promotes negative feedback regulation of TLR signaling via targeting microRNA-155-SOCS1 in macrophages. J Immunol 2013; 190: 3687-3695.
48. Zhang Y, Leung DY, Richers BN et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 2012; 188: 2127-2135.
49. Takeyama K, Masuhiro Y, Fuse H et al. Selective interaction of Vitamin D receptor with transcriptional coactivators by a Vitamin D analog. Mol Cell Biol 1999; 19: 1049-1055.
50. Ito I, Waku T, Aoki M et al. A nonclassical Vitamin D receptor pathway suppresses renal fibrosis. J Clin Invest 2013; 123: 4579-4594.
51. Nakano Y, Kato Y, Imai K et al. Practical synthesis and evaluation of the biological activities of 1alpha,25-dihydroxyVitamin D3 antagonists, 1alpha,25-dihydroxyVitamin D3-26,23-lactams. Designed on the basis of the helix 12-folding inhibition hypothesis. J Med Chem 2006; 49: 2398-2406.
52. Yoshizawa T, Handa Y, Uematsu Y et al. Mice lacking the Vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997; 16: 391-396.
53. Wagner D, Hanwell HE, Vieth R. An evaluation of automated methods for measurement of serum 25-hydroxyVitamin D. Clin Biochem 2009; 42: 1549-1556.
54. Namba T, Takabatake Y, Kimura T et al. Autophagic clearance of mitochondria in the kidney copes with metabolic acidosis. J Am Soc Nephrol 2014; 25: 2254-2266.
55. Li H, Cuartas E, Cui W et al. IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation. J Exp Med 2005; 201: 1169-1177.
56. Kimura T, Takabatake Y, Takahashi A et al. Autophagy protects the proximal tubule from degeneration and acute ischemic injury. J Am Soc Nephrol 2011; 22: 902-913.